CRISPR Therapeutics
CRISPR Therapeutics AG is a Swiss gene editing biopharmaceutical company developing transformative gene-based medicines utilizing Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9) technology. The company commercializes Casgevy for transfusion-dependent beta-thalassemia and severe sickle cell disease in collaboration with Vertex, alongside advancing immuno-oncology and regenerative medicine pipelines. Principal revenues derive from commercial sales of gene therapies, upfront milestone payments, and strategic research partnerships. Core end markets encompass specialized medical centers, hematology treatment facilities, and patients with severe genetic disorders in North America and Europe. CRISPR Therapeutics holds a pioneer market position in the biotechnology industry as the co-developer of the world's first approved CRISPR-based gene editing therapy. The company is headquartered in Zug, Switzerland, and its ordinary shares trade on the Nasdaq Global Select Market.
4 of the funds FundTelligence covers report a position in CRISPR Therapeutics.
- Legal name
- CRISPR Therapeutics AG
- Sector
- Health Care
- Country
- Switzerland
- Funds holding it
- 4
- Exposure themes
- Gene Editing, Genetic Medicine, Precision Medicine & Genomics
Funds holding CRISPR Therapeutics
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.31 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.06 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.04 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.04 % (full portfolio disclosed, September 2026)